epocrates logo
epocrates logo
epocrates logo
  • 0

Internally Generated Content

ESMO Congress 2026

Sacituzumab tirumotecan extends survival in previously treated endometrial cancer

October 26, 2026

card-image

Clinical takeaway: For patients with advanced or recurrent endometrial cancer previously treated with platinum-based chemotherapy and anti-PD-1/PD-L1 therapy, sacituzumab tirumotecan significantly improved progression-free survival, overall survival, and tumor response rates compared with physician's choice chemotherapy. The findings support sacituzumab tirumotecan as a potential new treatment option in a setting with limited effective therapies.

Treatment options for endometrial cancer that progresses after chemotherapy and immunotherapy are scarce, and outcomes are generally poor. TROP2 is commonly overexpressed in endometrial cancer, making it an attractive therapeutic target for antibody-drug conjugates such as sacituzumab tirumotecan.

In the phase 3 TroFuse-005/ENGOT-en23/GOG-3095 trial, 776 patients were randomized 1:1 to receive sacituzumab tirumotecan or physician's choice of doxorubicin or paclitaxel. Median follow-up was 14 months.

Sacituzumab tirumotecan nearly doubled median progression-free survival, extending it from 3.9 months with chemotherapy to 7.2 months, a gain of 3.3 months. Median overall survival improved from 12.1 months to 19.0 months, a gain of nearly 7 months. Compared with chemotherapy, treatment with sacituzumab tirumotecan reduced the risk of disease progression or death by about 41% and reduced the risk of death by about 32%.

Tumor responses were also substantially improved. The objective response rate reached 35.1%, compared with 17.3% for chemotherapy, while responses lasted a median of 11.1 months versus 6.9 months. Among responders, 43% maintained their response for at least 12 months.

Treatment-related adverse events of grade 3 or higher occurred in 54.4% of patients receiving sacituzumab tirumotecan versus 41.4% receiving chemotherapy. Anemia was the most common severe adverse event. Despite higher rates of toxicity, discontinuation due to treatment-related adverse events was uncommon (3.1% vs 4.9%), and global health status and quality of life were maintained over time in both groups.

Findings were presented at ESMO Congress 2026 and have not yet been peer-reviewed.

“Sacituzumab tirumotecan provided statistically significant and clinically meaningful improvements in progression-free survival, overall survival, and objective response rate versus treatment of physician's choice,” investigators reported, concluding that the findings support sacituzumab tirumotecan as “a new treatment option for this population.”

Source: ESMO Congress 2026. (2026 Oct 23) Late-Breaking Abstract 1268. Sacituzumab Tirumotecan in Previously Treated Advanced or Recurrent Endometrial Cancer: Results from the Phase 3 TroFuse-005/ENGOT-en23/GOG-3095 Study

learn more about epocrates plus

Clinical FAQs

Check out the answers to frequently asked questions about our clinical content.

Download Epocrates from the App StoreDownload Epocrates from the Play Store
About UsFeaturesBusiness SolutionsHelp & FeedbackCookie Preferences
© 2026 epocrates, Inc.   Terms of UsePrivacy PolicyEditorial PolicyDo Not Sell or Share My Information